Blood Cancer Video Library - Spanish Language - What are the risks and benefits of Ibrutinib and Idelalisib? How do you manage the side effects of the new kinase inhibitors?

Article and Video CATEGORIES

Cancer Journey

ABOUT

Dr. Marco Ruiz is a Medical Oncologist in Hematologic Cancers specializing in leukemia, lymphoma, myelodysplastic syndrome, myelofibrosis, HIV related malignancies, stem cell transplants, geriatric oncology, and palliative medicine at the Miami Cancer Institute in Miami, Florida. He is also an experienced bone marrow transplant specialist and is active in cancer research. Growing up the son of a nurse, Dr. Ruiz knew at a young age that he wanted to pursue a career in medicine. But it was his father’s battle with cancer that sparked a passion for helping patients with the disease.

Spanish Blood Cancer Library - What are the risks and benefits of Ibrutinib and Idelalisib?

dbrock

Fri, 10/13/2017 - 11:39

¿Cuáles son los riesgos y beneficios de ibrutinib y de idelalisib? ¿Cómo manejamos los efectos secundarios de los nuevos inhibidores de la tirosina cinasa?

Author

Marco A. Ruiz, MD, GRACE Faculty

For this video on the risks and benefits of Ibrutinib Idelalisib, GRACE sat down with Marco Ruiz, MD, an oncologist at Memorial Cancer Institute specializing in hematologic or blood cancers, including leukemia, lymphoma, myelodysplastic syndrome (MDS) and myelofibrosis. He is also an experienced bone marrow transplant specialist and is active in cancer research.

In this series Ibrutinib Idelalisib, Dr. Ruiz shares information regarding Chronic Lymphocytic Leukemia & Non-Hodgkin Lymphoma, (Leucemia crónica linfocítica y linfoma no Hodgkin). This video discusses "What are the risks and benefits of Ibrutinib and Idelalisib? How do you manage the side effects of the new kinase inhibitors?" (¿Cuáles son los riesgos y beneficios de ibrutinib y de idelalisib? ¿Cómo manejamos los efectos secundarios de los nuevos inhibidores de la tirosina cinasa?)

We would like to thank the following company for their support of this program:

Next Previous link

Previous Post Next Post

Article

Las biopsias líquidas están revolucionando la forma en que combatimos el cáncer, ofreciendo un futuro donde la detección y el tratamiento son más rápidos, precisos y menos invasivos.

Videoteca de Cáncer de Pulmón en Español 2025

Video

Como parte de la Videoteca de Cáncer de Pulmón en Español 2025, oncólogos expertos discuten las opciones de tratamiento y la información más emergente en cáncer de pulmón. El Dr. Raez aborda la terapia para cánceres de pulmón EGFR y ALK, además de analizar otros tres temas de actualidad. La Dra. Viola y la Dra. Riaño también contribuyen a esta videoteca, cada una presentando tres temas relevantes sobre el cáncer de pulmón.

Unlocking Precision in Lung Cancer: Understanding and Overcoming Resistance to EGFR and ALK Inhibitors

Article

The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.